Gastro-enteropancreatic neuroendocrine tumor: all 73 studies
Page 1 of 1. Open to participants first (25), then studies with results posted, then the rest; newest registration first within each.
- A Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)Not yet recruitingNCT07935928Phase 2/3
- TRINITY TRIAL; Trial Of PRRT Plus CAPTEM Vs CAPTEM Alone In Well Differentiated GEP NETSNot yet recruitingNCT07910760Phase 3
- Incremental Value of Delayed 68Ga-DOTATATE PET/MR in the Detection of Liver MetastasesRecruitingNCT07898904
- A Study of Treatment Patterns and Outcomes in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsRecruitingNCT07635316
- Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University HospitalRecruitingNCT07302100
- Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine TumorsRecruitingNCT07165886Phase 2/3
- Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.RecruitingNCT07165132Phase 1
- Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.RecruitingNCT07150546Phase 1
- Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NETRecruitingNCT06784752Phase 3
- Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsRecruitingNCT06441331Phase 1
- Observational Study on GEP-and Pulm-NET Treated at FPGRecruitingNCT06402695
- Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENsRecruitingNCT06356467
- Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National CohortRecruitingNCT06256705Not applicable
- 68Ga-DOTATOC PET for the Evaluation of Gastroenteropancreatic Neuroendocrine TumoursRecruitingNCT06155318
- An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.RecruitingNCT05884255Phase 3
- Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine NeoplasmsEnrolling by invitationNCT05709171Phase 2
- Continuing Somatostatin Analogues Upon Progression in Neuroendocrine Tumour pAtientsRecruitingNCT05701241Phase 4
- Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive TumorsRecruitingNCT05636618Phase 1/2
- Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NETEnrolling by invitationNCT05385861Phase 1/2
- Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)RecruitingNCT05359146Early Phase 1
- Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)RecruitingNCT05196087
- Spanish Series of Patients Treated With the Radionuclide Lutetium177RecruitingNCT04949282
- A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)RecruitingNCT04893785Phase 2
- Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine TumorsRecruitingNCT04090034
- A Phase I/II Study of Regorafenib Plus Avelumab in Solid TumorsRecruitingNCT03475953Phase 1/2
- Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR InhibitorsCompletedNCT05997056Phase 2Results posted
- Nutrition in Gastroenteropancreatic Neuroendocrine TumorCompletedNCT04986085Results posted
- Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Phase 3Results posted
- Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLsActive, not recruitingNCT04711135Phase 2Results posted
- Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) PatientsCompletedNCT04524442Phase 4Results posted
- Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal CancerCompletedNCT04505553Phase 2Results posted
- Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.CompletedNCT03980925Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NETActive, not recruitingNCT03972488Phase 3Results posted
- To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)CompletedNCT03220217Phase 2Results posted
- Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine TumorsCompletedNCT03043664Phase 1/2Results posted
- FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine CarcinomasTerminatedNCT03042780Phase 2Results posted
- Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NETCompletedNCT02231762Phase 2Results posted
- 68Ga-OPS202 Study for Diagnostic Imaging of GEP NETCompletedNCT02162446Phase 1/2Results posted
- A Study of Peptide Receptor Radionuclide Therapy (PRRT) Use in Neuroendocrine Tumor (NET) Patients in GermanyCompletedNCT07653126
- IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE CancersActive, not recruitingNCT06790706Phase 2
- A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and AcromegalyCompletedNCT06253897
- Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine TumorsCompletedNCT06091748Phase 3
- Multicenter Trial of ESK981 in Patients With Select Solid TumorsActive, not recruitingNCT05988918Phase 2
- Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver MetastasesTerminatedNCT05987176Phase 2
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingNCT05477576Phase 3
- 68Ga-DOTATOC Radio-Guided Surgery With β-Probe in GEP-NETActive, not recruitingNCT05448157
- A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)TerminatedNCT05364944Phase 1
- NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine CarcinomasCompletedNCT05262556Phase 1
- Neuroendocrine Tumors - Patient Reported OutcomesActive, not recruitingNCT05064150
- A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETActive, not recruitingNCT05050942Phase 3
- Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSEActive, not recruitingNCT04919226Phase 3
- 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETsWithdrawnNCT04915144Phase 2
- Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETsCompletedNCT04727723
- A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine TumorsWithdrawnNCT04614766Phase 1/2
- Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive SurgeryActive, not recruitingNCT04609592Phase 1
- Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 TypeStatus unknownNCT03963193Phase 2
- Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine TumorsActive, not recruitingNCT03891784Phase 2
- The Lyon Real World Evidence in Metastatic NeuroEndocrine TumoursStatus unknownNCT03863106
- A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)Active, not recruitingNCT03833700Phase 1
- Study of CVM-1118 for Patients With Advanced Neuroendocrine TumorsActive, not recruitingNCT03600233Phase 2
- A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3Status unknownNCT03457844Phase 2
- Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)CompletedNCT03017690
- Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine TumorsCompletedNCT02948946
- Pasireotide Treatment for Neuroendocrine TumorWithdrawnNCT02779257Phase 4
- Community-based Neuroendocrine Tumor (NET) Research StudyCompletedNCT02730104
- Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETsCompletedNCT02630654
- Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid TumorsCompletedNCT02611024Phase 1/2
- [68 Ga]-DOTANOC PET/CT in GEP-NETsCompletedNCT02608203Phase 2/3
- Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine TumorsTerminatedNCT02078843Phase 1/2
- A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine TumorTerminatedNCT01994213Phase 2
- TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine TumorsCompletedNCT01747096Not applicable
- A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal TumorsCompletedNCT01476592Not applicable
- The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver MetastasesCompletedNCT01423734